Pancreatic adenocarcinoma is the seventh leading cause of cancer death in the world and
the most common type pf pancreatic cancer. Unfortunately, less than 20% of patients are …

Poorly differentiated pancreatic neuroendocrine carcinomas (pNECs) are rare, highly
aggressive neoplasms. Frequently metastatic at diagnosis, prognosis is poor with median …

Neuroendocrine carcinomas (NEC) of the pancreas are defined by a mitotic count> 20
mitoses/10 high power fields and/or Ki67 index> 20%, and included all the tumors …

Objectives Therapeutic options for pancreatic neuroendocrine neoplasia (Pan-NEN) have
increased over the last decade. We aim to understand the evolution of the prognosis of …

Poorly differentiated neuroendocrine carcinoma is a rare malignancy that remains a
challenge to treat. Poorly differentiated neuroendocrine carcinoma occurs at an incidence of …

Objective Pancreatic neuroendocrine cancer is a rare, indolent malignancy with no effective
systemic therapy currently available. This population-based analysis evaluated the …

Poorly differentiated pancreatic neuroendocrine carcinoma (PD pNECs) is a rare disease
that has a poor prognosis and is treated with systemic chemotherapy as the standard of …

Pancreatic neuroendocrine neoplasms (PNENs) are rare, accounting for less than 5% of all
pancreatic tumors. High-grade pancreatic neuroendocrine carcinomas (hgPNECs) …

Background Limited data are available for pancreatic neuroendocrine carcinomas (NEC)
defined by 2010 World Health Organization (WHO) criteria (mitotic count> 20 mitoses/10 …

Abstract In 2017 the World Health Organization revised the criteria for classification of
pancreatic neuroendocrine neoplasms (pNENs) after a consensus conference at the …